Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies

IDCRC researchers begin clinical trial to assess schistosomiasis vaccine

The trial could help pave the way for the world’s first vaccine against the disease, offering a safe and cost-effective option to lower its prevalence worldwide and prevent deaths.

IDCRC researchers assess meningococcal vaccine for infants and young children in Africa

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

IDCRC Sites Across the Nation

View World Map

News from VTEU Trials

Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data

This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death.

Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines

Published in Science Translational Medicine

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

Primary immunogenicity objectives were to demonstrate non-inferiority of the neutralizing antibody (nAb) response against SARS-CoV-2 based on the geometric mean titer (GMTs) and the seroresponse rates (SRRs) (booster dose vs. primary series in a historical control group). nAbs against SARS-CoV-2 variants were also evaluated.

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial

Published in Nature Medicine

IDCRC Leadership Group

IDCRC Vaccine & Treatment Evaluation Units (VTEUs)

IDCRC Concept Quick Stats

ICP Status

Approved: 31
Administratively Not Supported: 19
Revise & Resubmit: 6
Withdrawn: 8
Liaisons: 0
EWGs: 7
Not Approved: 34
EMT: 2
Other: 8

EWG Assignment

COVID: 82
Respiratory: 11
STI: 7
Malaria/Topical Diseases: 5
Enteric Infections: 4
Emerging Infections: 6

ECP

Protocol Development: 6
IDCRC Concept Study Underway: 4
Moved forward through other processes: 4
Pending: 4
Not approved: 0
In Process: 5
Hold: 8
Withdrawn: 3
Note: Protocols Transitioned to IDCRC for Protocol Implementation: 5
Other studies in process not from IDCRC concepts: (MOMI-VAX, Moderna Pediatric, Moderna Variant, Moderna Boost): 5

IDCRC Citation Statement

Please include the following citation in any publications resulting from direct or indirect IDCRC support:

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

Publications